Mesalamine is an aminosalicylate indicated for mildly to moderately active ulcerative colitis and maintenance of remission. We supply it to US manufacturers of delayed-release tablets, extended-release capsules, rectal suspension and suppositories.
Data from PubChem (CID 4075) and FDA’s substance registry
CAS number
89-57-6
Molecular formula
C7H7NO3
Molecular weight
153.1g/mol
FDA UNII
IUPAC name
5-amino-2-hydroxybenzoic acid
InChIKey
KBOPZPXVLCULAV-UHFFFAOYSA-N
- Appearance
- Light tan to pink, needle-shaped crystals.
- Solubility
- Slightly soluble in water. Soluble in dilute hydrochloric acid and in dilute alkali hydroxides.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Darkens as it oxidizes, so color and packaging are worth specifying. Doses are high, which makes bulk and tapped density matter for tablets and capsules.
On the US market
- Reference product
- PentasaNDA 020049
- Approved ANDAs
- 32 with a marketed product
- Approved forms and strengths
- Extended-release capsule 250 mg, 375 mg, 500 mg
- Delayed-release tablet 800 mg, 1.2 g
- Suppository 1 g
- Rectal enema 4 g/60 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com